MY140504A - Statin-mmp inhibitor combinations - Google Patents
Statin-mmp inhibitor combinationsInfo
- Publication number
- MY140504A MY140504A MYPI99000951A MYPI9900951A MY140504A MY 140504 A MY140504 A MY 140504A MY PI99000951 A MYPI99000951 A MY PI99000951A MY PI9900951 A MYPI9900951 A MY PI9900951A MY 140504 A MY140504 A MY 140504A
- Authority
- MY
- Malaysia
- Prior art keywords
- statin
- mmp inhibitor
- inhibitor combinations
- combinations
- mmp
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
THE INVENTION IS A PHARMACEUTICAL COMPOSITION COMPRISING AN MMP INHIBITOR AND A STATIN, SAID COMPOSITION BEING USEFUL FOR TREATING VASCULAR DISEASES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7826598P | 1998-03-17 | 1998-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
MY140504A true MY140504A (en) | 2009-12-31 |
Family
ID=22142950
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MYPI99000951A MY140504A (en) | 1998-03-17 | 1999-03-15 | Statin-mmp inhibitor combinations |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1063991A1 (en) |
JP (1) | JP2002506818A (en) |
KR (1) | KR20010041916A (en) |
AR (1) | AR018113A1 (en) |
AU (1) | AU1591699A (en) |
BR (1) | BR9815745A (en) |
CA (1) | CA2309588A1 (en) |
CO (1) | CO5070670A1 (en) |
GT (1) | GT199900039A (en) |
HN (1) | HN1999000029A (en) |
MY (1) | MY140504A (en) |
NZ (1) | NZ505994A (en) |
PA (1) | PA8469001A1 (en) |
PE (1) | PE20000348A1 (en) |
SV (1) | SV1999000026A (en) |
UY (1) | UY25436A1 (en) |
WO (1) | WO1999047138A1 (en) |
ZA (1) | ZA992106B (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0100761D0 (en) | 2001-01-11 | 2001-02-21 | Biocompatibles Ltd | Drug delivery from stents |
MX2007006279A (en) | 2004-12-15 | 2007-06-14 | Solvay Pharm Gmbh | Pharmaceutical compositions comprising nep-inhibitors, inhibitors of the endogenous endothelin producing system and hmg coa reductase inhibitors. |
AU2006313430B2 (en) * | 2005-11-08 | 2012-09-06 | Ranbaxy Laboratories Limited | Process for (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4- [(4-hydroxy methyl phenyl amino) carbonyl]-pyrrol-1-yl]-3, 5-dihydroxy-heptanoic acid hemi calcium salt |
EP2310417A4 (en) * | 2008-07-11 | 2012-01-11 | Forskarpatent I Syd Ab | Oxidized ldl specific antibody-fusion and conjugated proteins |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1217656C (en) * | 1995-11-02 | 2005-09-07 | 沃尼尔·朗伯公司 | Method and pharmaceutical composition for regulating lipid concentration |
WO1997044315A1 (en) * | 1996-05-17 | 1997-11-27 | Warner-Lambert Company | Biphenylsulfonamide matrix metalloproteinase inhibitors |
IL128545A0 (en) * | 1996-12-09 | 2000-01-31 | Warner Lambert Co | Method for treating and preventing heart failure and ventricular dilatation |
TW536540B (en) * | 1997-01-30 | 2003-06-11 | Bristol Myers Squibb Co | Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe |
GT199800126A (en) * | 1997-08-29 | 2000-01-29 | COMBINATION THERAPY. |
-
1998
- 1998-11-20 EP EP98960279A patent/EP1063991A1/en not_active Withdrawn
- 1998-11-20 JP JP2000536378A patent/JP2002506818A/en active Pending
- 1998-11-20 CA CA002309588A patent/CA2309588A1/en not_active Abandoned
- 1998-11-20 WO PCT/US1998/024681 patent/WO1999047138A1/en not_active Application Discontinuation
- 1998-11-20 AU AU15916/99A patent/AU1591699A/en not_active Abandoned
- 1998-11-20 KR KR1020007010223A patent/KR20010041916A/en not_active Application Discontinuation
- 1998-11-20 NZ NZ505994A patent/NZ505994A/en unknown
- 1998-11-20 BR BR9815745-0A patent/BR9815745A/en not_active Application Discontinuation
-
1999
- 1999-02-24 AR ARP990100751A patent/AR018113A1/en unknown
- 1999-03-15 MY MYPI99000951A patent/MY140504A/en unknown
- 1999-03-16 PE PE1999000217A patent/PE20000348A1/en not_active Application Discontinuation
- 1999-03-16 ZA ZA9902106A patent/ZA992106B/en unknown
- 1999-03-16 PA PA19998469001A patent/PA8469001A1/en unknown
- 1999-03-16 UY UY25436A patent/UY25436A1/en not_active Application Discontinuation
- 1999-03-16 CO CO99016109A patent/CO5070670A1/en unknown
- 1999-03-16 GT GT199900039A patent/GT199900039A/en unknown
- 1999-03-16 HN HN1999000029A patent/HN1999000029A/en unknown
- 1999-03-16 SV SV1999000026A patent/SV1999000026A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CO5070670A1 (en) | 2001-08-28 |
JP2002506818A (en) | 2002-03-05 |
BR9815745A (en) | 2000-11-14 |
PA8469001A1 (en) | 2002-09-17 |
UY25436A1 (en) | 2001-10-25 |
KR20010041916A (en) | 2001-05-25 |
EP1063991A1 (en) | 2001-01-03 |
NZ505994A (en) | 2003-10-31 |
AR018113A1 (en) | 2001-10-31 |
HN1999000029A (en) | 1999-09-29 |
AU1591699A (en) | 1999-10-11 |
GT199900039A (en) | 2000-09-06 |
SV1999000026A (en) | 2000-01-18 |
CA2309588A1 (en) | 1999-09-23 |
ZA992106B (en) | 1999-09-30 |
PE20000348A1 (en) | 2000-05-22 |
WO1999047138A1 (en) | 1999-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NL300179I1 (en) | Drug precursors of thrombin inhibitors. | |
YU15299A (en) | Pharmaceutical compositions | |
ES2114487B1 (en) | SYNERGISTIC STABILIZING MIX. | |
BG104780A (en) | Inhibitors of phospholipase enzymes | |
WO1999054286A3 (en) | Btk inhibitors and methods for their identification and use | |
NO990760D0 (en) | 1,4-heterocyclic metal protease inhibitors | |
UA34466C2 (en) | Agent for non-systemic control of parasites | |
AU7031500A (en) | Therapeutic quinazoline compounds | |
ID18141A (en) | 1,3-DIHETEROSICLIC METALOPROTEASE INHIBITORS | |
UA85368C2 (en) | Use of osteopontin for the treatment and/or prevention of neurologic diseases | |
ES2191830T3 (en) | THROMBIN INHIBITORS. | |
EP1776954A3 (en) | The use of inhibitors of the renin-angiotensin system for the treatment of stroke | |
AU2001260880A1 (en) | Pharmaceutical compounds for treating copd | |
ZA9811629B (en) | The use of MMP inhibitors for the treatment of ocular angiogenesis. | |
YU34199A (en) | Use of gastrointestinal lipase inhibitors | |
MY118381A (en) | Statin-carboxyalkylether combinations | |
GB9907571D0 (en) | Compounds | |
EP0858262A4 (en) | Thrombin inhibitors | |
ZA985182B (en) | Farnesyl transferase inhibitors in combination with HMG COA reductase inhibitors for the treatment of cancer. | |
NZ320259A (en) | Deodorizing preparations containing cationic biopolymers, aluminium hydrochlorate and esterase inhibitors | |
MY140504A (en) | Statin-mmp inhibitor combinations | |
IL139144A0 (en) | Mycobacterial inhibitors | |
AU1103699A (en) | Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia | |
EP1351680B8 (en) | Use of anethole-dithiolethione for preventing and treating drug-induced tendon toxicity | |
BR0112460A (en) | Method for sepsis treatment |